Zobrazeno 1 - 10
of 34
pro vyhledávání: '"Nienke Z. Borren"'
Autor:
Alexander Levy, Nienke Z. Borren, Benjamin Maxner, William Tan, Danielle Bellavance, Kyle Staller, Daniel Chung, Hamed Khalili, Ashwin N. Ananthakrishnan
Publikováno v:
BMC Gastroenterology, Vol 19, Iss 1, Pp 1-7 (2019)
Abstract Background The long-term natural history of microscopic colitis (MC) (collagenous colitis (CC), lymphocytic colitis (LC)), traditionally considered relapsing but non-progressive diseases, is poorly defined. Whether persistent histologic infl
Externí odkaz:
https://doaj.org/article/ae9ad98573af4b92870e83325874215f
Publikováno v:
Current Opinion in Gastroenterology. 38:382-387
Purpose of review In this article, we provide an overview of studies examining multiomic profiling in various clinical scenarios in the management of inflammatory bowel diseases (IBDs). Recent findings IBD arises as a result of an interplay between g
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::46c37129a4e507c0185946174b3d10db
https://doi.org/10.1097/mog.0000000000000847
https://doi.org/10.1097/mog.0000000000000847
Publikováno v:
Inflamm Bowel Dis
Inflammatory Bowel Diseases, 27(11), 1740-1746. Oxford University Press
Inflammatory Bowel Diseases, 27(11), 1740-1746. Oxford University Press
Background Fatigue is a disabling symptom in patients with inflammatory bowel disease (IBD). Its prevalence, mechanism, and impact remain poorly understood. We determined changes in fatigue status over time and identified predictors of incident or re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fe646de100903ecfa557c821b5d5f814
https://pure.eur.nl/en/publications/cadb90b1-f215-46da-a7ea-69b7a0a89d09
https://pure.eur.nl/en/publications/cadb90b1-f215-46da-a7ea-69b7a0a89d09
Autor:
Nienke Z. Borren, Emma Paulides, C. Janneke van der Woude, Jody L. Frinack, Maria Alice V. Willrich, Ryan N. Olson, Ashwin N. Ananthakrishnan
Publikováno v:
Digestive Diseases and Sciences, 66(10), 3548-3554. Springer New York
Background: Therapeutic drug monitoring (TDM) is important in optimizing use of biologics in inflammatory bowel diseases (IBD). However, the role of proactive TDM during remission remains uncertain. Methods: This retrospective study included patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b7067dc15a36e36de0050403ad47e12a
http://www.scopus.com/inward/record.url?scp=85092303710&partnerID=8YFLogxK
http://www.scopus.com/inward/record.url?scp=85092303710&partnerID=8YFLogxK
Autor:
John J. Garber, Ashwin N. Ananthakrishnan, Jay Luther, Francis Colizzo, Nienke Z. Borren, Pei-Hsuan Mimi Li, Alison T. Jess, William Tan, Hamed Khalili
Publikováno v:
Digestive Diseases and Sciences. 65:3672-3678
Prior studies have inconsistently suggested that biologic therapy may be associated with weight gain in inflammatory bowel disease patients (IBD). Our aim was to compare weight gain across different biologic therapy classes with distinct mechanisms o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::14f3f6cc3de5ddd657ed891358a26f73
https://doi.org/10.1007/s10620-020-06442-9
https://doi.org/10.1007/s10620-020-06442-9
Autor:
Niharika Nalagatla, Saranya Sasidharan, David Faleck, Nienke Z. Borren, Ryan C. Ungaro, Benjamin L. Cohen, Tomer Adar, Kelly C. Cushing, Ashwin N. Ananthakrishnan, Anish Patel, Wayne A. Sy, Samuel C. Owen
Publikováno v:
Alimentary Pharmacology & Therapeutics. 49:873-879
BACKGROUND: The older patient with inflammatory bowel diseases (IBD) is particularly vulnerable to consequences of disease and therapy-related side effects but little is known about the best treatment options in this population. AIM: To compare safet
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::854d508bc14964de8e5e1178e02bc06e
https://doi.org/10.1111/apt.15177
https://doi.org/10.1111/apt.15177
Publikováno v:
Nature reviews-gastroenterology & hepatology, 16(4), 247-259. Nature Publishing Group
Fatigue is an important clinical problem in patients with IBD, affecting nearly 50% of patients in clinical remission and > 80% of those with active disease. The resulting decrease in quality of life and impaired work productivity and functioning con
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f8efcbabfb851442ac3a3bd2c5470b0c
https://doi.org/10.1038/s41575-018-0091-9
https://doi.org/10.1038/s41575-018-0091-9
Autor:
Clary B. Clish, Helena Lau, Ashwin N. Ananthakrishnan, Ramnik J. Xavier, Larson Hogstrom, Hera Vlamakis, Jonathan Wei Jie Lee, Hamed Khalili, Sara M. Gregory, Damian R. Plichta, Nienke Z. Borren, William Tan
Publikováno v:
Cell hostmicrobe. 29(8)
Summary The intestinal microbiome is a key determinant of responses to biologic therapy in inflammatory bowel disease (IBD). However, diverse therapeutics and variable responses among IBD patients have posed challenges in predicting clinical therapeu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c480701e4699d1fd57b3d49088dad540
https://pubmed.ncbi.nlm.nih.gov/35339462
https://pubmed.ncbi.nlm.nih.gov/35339462
Autor:
Nienke Z, Borren, Emma, Paulides, Jody L, Frinack, Ryan N, Olson, Maria Alice V, Willrich, C Janneke, van der Woude, Ashwin N, Ananthakrishnan
Publikováno v:
Digestive diseases and sciences. 66(10)
Therapeutic drug monitoring (TDM) is important in optimizing use of biologics in inflammatory bowel diseases (IBD). However, the role of proactive TDM during remission remains uncertain.This retrospective study included patients receiving infliximab
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::f2ed89aede0ae088848423c295fba884
https://pubmed.ncbi.nlm.nih.gov/33433791
https://pubmed.ncbi.nlm.nih.gov/33433791
Autor:
Nienke Z, Borren, William, Tan, Alison T, Jess, Pei-Hsuan Mimi, Li, John J, Garber, Jay, Luther, Francis P, Colizzo, Hamed, Khalili, Ashwin N, Ananthakrishnan
Publikováno v:
Digestive diseases and sciences. 65(12)
Prior studies have inconsistently suggested that biologic therapy may be associated with weight gain in inflammatory bowel disease patients (IBD). Our aim was to compare weight gain across different biologic therapy classes with distinct mechanisms o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::0b0571a59f3f26c6a53f09cfb4696fc9
https://pubmed.ncbi.nlm.nih.gov/32833158
https://pubmed.ncbi.nlm.nih.gov/32833158